Thursday, October 22, 2020

The PBS on-demand streaming service, WPBS Passport, is now available in Canada! Learn More

Home Video Opioids, Inc. (full film) | FRONTLINE

Opioids, Inc. (full film) | FRONTLINE

Pushing opioids. Bribing doctors. Making millions. FRONTLINE and the Financial Times investigate how Insys Therapeutics profited from a fentanyl-based painkiller up to 100 times stronger than heroin — and how some Wall Street investors looked the other way.

This journalism is made possible by viewers like you. Support your local PBS station here:
http://www.pbs.org/donate

“Opioids, Inc.” tells the inside story of how Insys profited from Subsys, a fast-acting fentanyl-based spray that’s been linked to hundreds of deaths.Tactics included targeting high-prescribing doctors and nurse practitioners known as “whales,” misleading insurers, and holding contests for the sales team: the higher the prescription doses they got doctors to write, the larger the cash prize — despite the dangers to patients.But as the documentary traces in unprecedented detail, the scheme fell apart: With federal prosecutors using anti-racketeering laws designed to fight organized crime, Insys became the first pharmaceutical company to have its CEOsentenced to prison timein federal courtin connection with the opioid crisis.

#Opioids #OpioidCrisis #WallStreet

Love FRONTLINE? Find us on the PBS Video App where there are more than 300 FRONTLINE documentaries available for you to watch any time: https://to.pbs.org/FLVideoApp

Subscribe on YouTube: http://bit.ly/1BycsJW
Instagram: https://www.instagram.com/frontlinepbs
Twitter: https://twitter.com/frontlinepbs
Facebook: https://www.facebook.com/frontline

Funding for FRONTLINE is provided through the support of PBS viewers and by the Corporation for Public Broadcasting. Major funding for FRONTLINE is provided by the John D.and Catherine T. MacArthur Foundation and the Ford Foundation. Additional funding is provided by the Abrams Foundation, the Park Foundation, The John and Helen Glessner Family Trust, and the FRONTLINE Journalism Fund with major support from Jon and Jo Ann Hagler onbehalf of the Jon L. Hagler Foundation.